Recurrent copy number variations (CNVs) are genetic alterations commonly observed in human tumors. One of the most frequent CNVs in human tumors involves copy number gains (CNGs) at chromosome 3q26, which is estimated to occur in >20% of human tumors. The high prevalence and frequent occurrence of 3q26 CNG suggest that it drives the biology of tumors harboring this genetic alteration. The chromosomal region subject to CNG (the 3q26 amplicon) spans from chromosome 3q26 to q29, a region containing ~200 protein-encoding genes. The large number of genes within the amplicon makes it difficult to identify relevant oncogenic target(s). Whereas a number of genes in this region have been linked to the transformed phenotype, recent studies indicate a high level of cooperativity among a subset of frequently amplified 3q26 genes. Here we use a novel bioinformatics approach to identify potential driver genes within the recurrent 3q26 amplicon in lung squamous cell carcinoma (LSCC). Our analysis reveals a set of 35 3q26 amplicon genes that are coordinately amplified and overexpressed in human LSCC tumors, and that also map to a major LSCC susceptibility locus identified on mouse chromosome 3 that is syntenic with human chromosome 3q26. Pathway analysis reveals that 21 of these genes exist within a single predicted network module. Four 3q26 genes, SOX2, ECT2, PRKCI and PI3KCA occupy the hub of this network module and serve as nodal genes around which the network is organized. Integration of available genetic, genomic, biochemical and functional data demonstrates that SOX2, ECT2, PRKCI and PIK3CA are cooperating oncogenes that function within an integrated cell signaling network that drives a highly aggressive, stem-like phenotype in LSCC tumors harboring 3q26 amplification. Based on the high level of genomic, genetic, biochemical and functional integration amongst these 4 3q26 nodal genes, we propose that they are the key oncogenic targets of the 3q26 amplicon and together define a "3q26 OncCassette" that mediates 3q26 CNG-driven tumorigenesis. Genomic analysis indicates that the 3q26 OncCassette also operates in other major tumor types that exhibit frequent 3q26 CNGs, including head and neck squamous cell carcinoma (HNSCC), ovarian serous cancer and cervical cancer. Finally, we discuss how the 3q26 OncCassette represents a tractable target for development of novel
Introduction
Cancer is a disease of progressive genetic alterations that conspire to drive a cellular phenotype characterized by uncontrolled growth, aggressive invasive behavior, enhanced survival, evasion of immune surveillance, and resistance to therapeutic interventions. Recent analysis of the genetic landscape of human cancers reveals that tumors can be classified into two main groups based upon the nature of the genetic alterations they harbor (Ciriello et al., 2013) . In M-type tumors, somatic mutations that either activate oncogenes or inactivate tumor suppressor genes are the predominant genetic alterations. In contrast, in C-type tumors recurrent gene copy number variations (CNVs) are the predominant genetic alterations (Ciriello, Miller, 2013) . Many of the key oncogenic driver mutations occurring in M-type tumors have been identified, molecularly characterized, functionally validated, and in some cases therapeutically targeted; prominent examples include EGFR, BRAF and PI3KCA mutations that are key drivers of oncogenic phenotypes (Samuels and Velculescu, 2004 , Serra et al., 2008 , Thomas et al., 2005 , Tie and Desai, 2015 . Likewise, prevalent recurring inactivating mutations in tumor suppressor genes, including those in TP53 (Hrstka et al., 2009) , CDKN2A (p16) , PTEN (Hollander et al., 2011) and APC (Polakis, 1997) , have been well-documented and molecularly characterized. However, much less is known about whether and how tumor-specific CNVs drive C-type cancers. Comparative Genomic Hybridization (CGH) studies and more recent global genomic initiatives, such as The Cancer Genome Atlas (TCGA) project, have revealed that C-type tumors exhibit frequent and recurrent CNVs, both CNGs, or deletions, often encompassing large chromosomal regions (including, in some cases, entire chromosomal arms). As a consequence, these CNV events involve genetic loss or gain of large numbers of genes within the affected region. Recurrent CNVs involving loss of specific chromosomal regions are in some cases associated with loss of specific tumor suppressor genes; the most prevalent CNV in human tumors involves loss of chromosome 9p21 containing the prominent tumor suppressor target CDKN2A (reviewed in (Liggett and Sidransky, 1998) ). However, for many recurrent CNVs involving chromosome loss, the relevant tumor suppressor(s) remain to be conclusively identified and functionally validated.
Recurrent CNGs suggest the presence of oncogenic driver(s) within these amplified regions. It is generally assumed that CNGs result in increased expression of one or more genes in the amplified region, thereby promoting or enhancing their oncogenic potential. Examples of CNGs driving oncogene activation through increased expression include amplification of CMYC at chromosome 8q24 (Little et al., 1983) , cyclin D1 (CCND1) at chromosome 11q23 (Nishida et al., 1994) , and EGFR at chromosome 7p11 (Wong et al., 1987) . However, unlike the situation involving specific oncogenic somatic mutations, in which a distinct mutation Miller, 2013 , Rooney et al., 1999 . Independent CGH analyses revealed prevalent 3q26 CNVs in cervical (77-90%) (Heselmeyer et al., 1997 , Heselmeyer et al., 1996 , esophageal (50-69%) (Bandla et al., 2012 , Pack et al., 1999 , Sakai et al., 2010 , HNSCC (50-91%) (Bockmuhl et al., 1998 , Brzoska et al., 1995 , Hashimoto et al., 2001 , Speicher, Howe, 1995 , LSCC (77-85%) (Balsara et al., 1997 , Bjorkqvist et al., 1998 , Brass et al., 1996 , Massion et al., 2002 , Petersen et al., 1997 , ovarian serous (36-51%) (Arnold et al., 1996 , Iwabuchi et al., 1995 and endometrial serous cancers (50%) (Pere et al., 1998) . 3q26 CNGs were also observed in 76% of small cell lung cancers (SCLC), though the estimate of prevalence in SCLC must be considered tentative given the extremely small sample size of these studies (Ried et al., 1994 , Sugita et al., 2000 . We therefore assessed the prevalence of 3q26 CNVs across major human tumor types using TCGA datasets available through the cBioPortal (http://www.cbioportal.org/index.do) (Figure 1 ). To estimate 3q26 CNGs, we interrogated the TCGA datasets for CNGs in two genes within the core of the consensus 3q26 amplicon (PRKCI and SOX2) using the GISTIC algorithm. These genes were chosen to represent 3q26 CNGs since they: 1) exhibit virtually identical GISTIC scores across the examined tumor types indicating near perfect co-occurrence of CNGs at these genes; and 2) routinely exhibit the highest CNG frequency of any 3q26 genes in the affected tumor types, indicating that these genes are essentially invariably part of the recurrent 3q26 amplicon. Analysis revealed extremely prevalent chromosome 3q26 CNGs in LSCC (85%), esophageal (85%), ovarian serous (85%), cervical (78%), HNSCC (75%) and bladder (60%) cancers. 3q26 CNGs were of intermediate prevalence (20-35%) in stomach, lung adenocarcinoma, breast, uterine and liver cancers, and of lower, but significant, prevalence (10-18%) in prostate, pancreatic, sarcoma, glioblastoma, kidney and colorectal cancers (Figure 1 ). Our analysis confirms earlier CGH studies demonstrating very high frequency 3q26 CNGs in many tumors types (i.e. LSCC, esophageal, HNSCC, ovarian and cervical cancers) (Chujo et al., 2002 , Sakai, Kajiyama, 2010 , Sonoda, Palazzo, 1997 , Speicher, Howe, 1995 , Sugita, Tanaka, 2000 and also revealed somewhat less prevalent, but significant CNGs in tumor types not previously identified as harboring this alteration. These data provide a comprehensive snapshot of the sweeping prevalence and distribution of 3q26 CNGs across major human cancer types.
3q26 amplification is an oncogenic driver of tumorigenesis
A major question with regard to the involvement of CNGs in human cancer is whether these genetic alterations represent oncogenic "drivers" of tumorigenesis. Several lines of experimental evidence indicate that 3q26 CNG is an oncogenic driver in affected tumors. First, 3q26 CNGs are observed in precancerous lesions, demonstrating that this is an early event in tumorigenesis. Using fluorescence bronchoscopy, sequential biopsies of a carcinoma in situ (CIS) lesion, and a LSCC identified at the site of the CIS lesion approximately 1.5 years after initial identification were analyzed (Foster et al., 2005) . Both the CIS and the subsequent LSCC lesion harbored specific 3q26 CNG, indicating occurrence of this event prior to progression to malignant LSCC (Foster, Banerjee, 2005) . Similarly, 3q26 CNGs were found to be present in both early stage pre-invasive lung squamous cell lesions and in invasive LSCCs, albeit at a higher frequency in the more advanced lesions (Pelosi et al., 2007) . These results demonstrate that 3q26 CNGs occur early during transformation, in some cases prior to the acquisition of a frank malignant phenotype, and that CNGs are enriched in more malignant lesions. Since 3q26 CNGs are detected in preinvasive lesions that progress to LSCC, 3q26 CNG, and/or increased expression of 3q26 target genes, has been proposed as a biomarker of early pre-cancerous lesions with a high potential for progression to invasive LSCC. Similar findings of 3q26 CNGs in early malignant or preneoplastic lesions have been observed in cervical cancer (Heselmeyer, Schrock, 1996) and HNSCC (Singh et al., 2002) . CGH analysis of normal cervical epithelium, dysplasias (subcategorized as mild, moderate and severe), and stage I invasive carcinomas, revealed that 3q26 CNGs are the most consistent chromosomal aberration occurring in dysplastic cells that progress to invasive cervical carcinoma (Heselmeyer, Schrock, 1996) . Likewise, a study of HNSCC found 3q26 CNGs in 3% of normal mucosa, 25% of premalignant tissue, and 56% of invasive HNSCCs (Singh, Stoffel, 2002) , while a second report found frequent 3q CNGs in low grade HNSCCs (Bockmuhl et al., 1996) . The finding that 3q26 CNGs occur in pre-neoplastic lesions, and at higher frequency in subsequent malignant lesions, suggests that 3q26 CNGs play an important functional role in the transition from the pre-malignant to malignant state, at least in LSCC, HNSCC and cervical cancer, three tumor types harboring frequent 3q26 CNGs.
The second line of evidence that 3q26 CNG is an oncogenic driver is the strong association of this alteration with poor clinical outcome. In primary HNSCC tumors, 3q26 CNG is associated with significantly higher rates of tumor recurrence and cancer-related death (Singh, Stoffel, 2002) , and with shorter disease-specific survival (Bockmuhl et al., 2000) when compared to tumors not harboring 3q26 CNG. Consistent with this observation, 3q26 CNG is more frequently observed in high grade ovarian serous tumors when compared to low grade tumors, suggesting an association with disease progression and acquisition of an aggressive phenotype in ovarian cancer (Balsara, Sonoda, 1997) . Similarly, 3q26 CNGs were found at significantly higher frequencies in metastatic esophageal squamous cell carcinomas when compared to those tumors that did not metastasize (Sakai, Kajiyama, 2010) . These findings support a role for 3q26 CNG in tumor aggressiveness, progression and/or clinical outcome in essentially all of the major tumor types that frequently harbor this alteration.
The third line of evidence that 3q26 CNG is an oncogenic driver comes from a genetic analysis of strain-specific differences in susceptibility to tobacco smoke carcinogen-induced LSCC in the mouse (Wang, Zhang, 2004) . In this study, an extensive genomic analysis was conducted to identify strain-specific genomic regions associated with increased susceptibility to the tobacco smoke carcinogen N-nitroso-tris-chloroethylurea (NNTC)-induced LSCC. Interestingly, 3 strain-specific LSCC susceptibility loci were identified that are significantly associated with LSCC tumor development (Wang, Zhang, 2004) . One of these loci localized to a region of mouse chromosome 3 that is syntenic with human chromosome 3q26; in contrast, the other two susceptibility loci do not map to regions of frequent CNG in human tumors. These data provide strong genetic evidence that 3q26-specific CNGs are involved in LSCC initiation in both mice and humans. Fields et al. Page 5 Adv Biol Regul. Author manuscript; available in PMC 2017 January 01.
A majority of 3q26 target genes map to a single predicted network module
CGH analyses have demonstrated that tumors with 3q CNGs arising at different anatomic sites share an overlapping area of chromosomal gain centered around 3q26 (Brass, Ukena, 1996 , Heselmeyer, Macville, 1997 , Singh, Stoffel, 2002 , Speicher, Howe, 1995 . Depending on the study, the amplified region was found to extend from 3q26 to as far as the telomere at 3q29 (Wang et al., 2013a) , a region encompassing 194 protein-encoding genes according to the Ensembl human gene database (Ensembl Genes-Build 37; http://www.ensembl.org) (Flicek et al., 2014) . In order to identify potential driver genes within this large affected region, we first identified genes within this region that also map to the syntenic mouse chromosome 3 region previously identified as a major susceptibility locus for carcinogeninduced LSCC in the mouse (Wang, Zhang, 2004) . Interrogation of the Mouse Genome Informatics database revealed that 146 of the 194 human genes mapping to human chromosome 3q26-29 have direct mouse homologs. Of these genes, 50 map to mouse chromosome 3. Interestingly, these genes are restricted to human chromosome 3q26.1-3q27, and span remarkably similar chromosomal expanses in human and mouse chromosome 3 (54.1 Mb in human; 55.9 Mb in mouse) ( Figure 2 ). Interestingly, this region appears to have undergone several rearrangement/inversion events through evolution but the gene cluster remains intact ( Figure 2 ). These data are consistent with several reports mapping the core of the 3q26 amplicon to chromosome 3q26.1-3q27 (Hagerstrand et al., 2013 , Sugita, Tanaka, 2000 . We reasoned that since these 50 genes are within the recurrent human 3q26 amplicon and map to a major LSCC susceptibility locus in the mouse, they are likely to be enriched in relevant targets of the 3q26 amplicon that drive LSCC development and maintenance. We further reasoned that the most critical target genes within this group would exhibit expression that is driven by 3q26 CNG in human tumors. Thus, to further focus our analysis, we interrogated the TCGA gene expression dataset consisting of 178 human LSCC tumor samples for expression of these 50 candidate 3q26 driver genes. For each gene, the LSCC tumor samples were divided into two sets; those harboring CNG for that gene as determined using the GISTIC algorithm (CNG defined as a GISTIC score of +1 or +2), and those not harboring CNG (GISTIC score of 0 or −1). We then determined whether the expression of that gene was significantly different between the groups (p≤0.05 by T-test). This analysis yielded 35 genes that satisfied the following criteria: 1) resides within the recurrent 3q26 amplicon; 2) maps within the centenic LSCC susceptibility locus on mouse chromosome 3; and 3) exhibits expression that is significantly associated with CNGs of the gene in human LSCC tumors ( Figure 2 ; genes indicated in bold italics). Remarkably, geneset analysis using the ConsensuPathDB-human (CPDB; http:// cpdb.molgen.mpg.de/CPDB) tool revealed a single induced network module containing 21 of these 35 genes ( Figure 3 ). The network module has at its core major hubs centered on SOX2, PRKCI, ECT2 and PIK3CA. These data suggest that the 3q26 amplicon serves to drive expression of a set of genes whose function is integrated around these nodal genes.
The core nodal 3q26 genes SOX2, PRKCI, ECT2 and PIK3CA are functionally involved in 3q26-driven cancers
The genomic analysis above indicates that 3q26 CNG drives tumorigenesis by coordinately overexpressing a set of core genes that functionally interact within a signaling network. A
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survey of the primary literature regarding the involvement of the 21 network genes identified above indicate that, for at least for some of these genes, there is good evidence for involvement in 3q26-driven cancers. These data are summarized in Table 1 . Perhaps not surprisingly, of the genes within this group, the most convincing evidence for a functional role in 3q26-driven cancers applies to the four nodal genes SOX2, PRKCI, ECT2 and PIK3CA occupying the core of the identified network. Below, we will focus our discussion on the published literature regarding the role of each of these nodal genes in 3q26-driven cancers.
SOX2 is a major transcriptional regulator of gene expression and is critical for both embryonic development and maintenance of the "stem" phenotype of pluripotent cells in adult tissues . SOX2 also plays a key role in the stem-like TIC phenotype, particularly in SCC (Bass et al., 2009 , Liu, Lin, 2013 . SOX2 is the most highly upregulated transcription factor in skin SCC TICs where it regulates genes associated with stemness (Boumahdi et al., 2014) . Conditional ablation of SOX2 in existing skin SCC tumors leads to tumor regression and decreased tumor transplantation, supporting a critical role for SOX2 in TIC cell maintenance (Boumahdi, Driessens, 2014) . Likewise, ectopic expression of SOX2 in HNSCC cells promotes "stemness" while SOX2 knockdown (KD) in HNSCC TICs reduces self-renewal, chemoresistance and tumorigenicity, demonstrating a functional role for SOX2 in 3q26 amplified cancers (Lee et al., 2014) .
SOX2 has been identified as a lineage-restricted oncogene in LSCC and HNSCC (Bass, Watanabe, 2009 ) that functions to maintain a stem-like phenotype in LSCC and HNSCC cells (Boumahdi, Driessens, 2014 , Hussenet, Dali, 2010 , Hussenet and du Manoir, 2010 , Lee, Oh, 2014 , Liu, Lin, 2013 , Lu et al., 2010 , Nakatsugawa et al., 2011 , Yuan et al., 2010 . Genetic silencing of SOX2 expression leads to apoptosis, loss of tumorgienicity and decreased stemness in lung cancer cells (Chen et al., 2014a , Lee, Oh, 2014 , Xiang et al., 2011 . Gene amplification drives SOX2 expression in lung, esophageal and other squamous cell cancers (Bass, Watanabe, 2009 , Justilien, Walsh, 2014 , Maier et al., 2011 . ShRNA-mediated knockdown of SOX2 expression and candidate neighboring genes in 3q26 amplified and non-amplified cancer cell lines revealed that inhibition of SOX2 expression had the largest differential anti-proliferative effect on 3q26 amplified SCC cell lines (Bass, Watanabe, 2009 ). Meta-analysis of SOX2 expression and clinical/prognostic features of HNSCC patients revealed that elevated SOX2 predicts poor overall and diseasefree survival, and SOX2 expression significantly correlates with higher tumor grade, and presence of lymph node and distant metastases (Dong et al., 2014) . SOX2 expression is similarly prognostic of poor outcome in lung adenocarcinoma (LADC) (Sholl et al., 2010) and small cell lung cancer (Xiang, Liao, 2011) . However, somewhat paradoxically, SOX2 expression has been associated with better clinical outcome for NSCLC patients, suggesting that multigenic factors drive aggressive behavior and poor outcome in 3q26-driven tumors , Iijima et al., 2015 , Toschi et al., 2014 , Velcheti et al., 2013 , Wang et al., 2015b . These studies strongly support a driver role for SOX2 in 3q26 amplified tumors and perhaps other tumor types.
ECT2 is a guanine nucleotide exchange factor for the Rho family of GTPases (Rho, Cdc42 and Rac) that functions primarily in the control of cytokinesis in non-transformed cells Fields et al. Page 7 Adv Biol Regul. Author manuscript; available in PMC 2017 January 01. (Tatsumoto et al., 1999) Ect2 was originally identified as a gene that can transform mouse fibroblasts (Miki et al., 1993) ; reviewed in ). Subsequent studies have demonstrated a role for ECT2 in the transformed phenotype of multiple tumor types including glioma (Salhia et al., 2008) , LSCC Fields, 2009, Justilien et al., 2011) and ovarian cancers (Huff et al., 2013) . Though ECT2 has been demonstrated to play a functional role in transformed behavior in a number of tumor types, the mechanism by which ECT2 participates in transformation is still incompletely understood. Recent experimental evidence strongly suggests that the oncogenic function of ECT2 is distinct from its role in regulating cytokinesis (Justilien, Jameison, 2011 ) and appears to involve as yet unidentified nuclear function(s) for this protein (Huff, Decristo, 2013 , Justilien, Jameison, 2011 .
Ect2 is highly expressed in a variety of human tumors including brain (Salhia, Tran, 2008 , Sano et al., 2006 lung Justilien, 2010, Hirata et al., 2009) , esophageal (Hirata, Yamabuki, 2009) , pancreatic and ovarian tumors (Haverty et al., 2009 ). Ect2 overexpression is associated with poor prognosis in patients with NSCLC and ESCC (Hirata, Yamabuki, 2009 ). Specifically, NSCLC and ESCC patients whose tumors exhibit strong Ect2 staining had a poorer prognosis than patients whose tumors showed weak or no Ect2 staining. In ESCC patients, high Ect2 expression also positively correlated with tumor size and tumor metastasis to lymph nodes (Hirata, Yamabuki, 2009) , suggesting that Ect2 expression is important for these clinicopathologic features of tumor progression. Ect2 expression may also serve as a prognostic indicator in glioblastoma patients, where high Ect2 expression was associated with a shorter survival time (Salhia, Tran, 2008 , Sano, Genkai, 2006 . Further investigation is required to determine if Ect2 expression is useful as a prognotic marker in other human cancer types.
ECT2 CNGs frequently occur in LSCC (>70%), but rarely in lung adenocarcinoma (LADC) ). These findings are consistent with the prevalence of chromosome 3q26 CNGs in LSCCs and the relatively rare occurrence of 3q26 CNGs in LADCs (Balsara, Sonoda, 1997 , Brass, Ukena, 1996 . Ect2 mRNA expression in LSCCs correlates with ECT2 CNGs, demonstrating that tumor specific ECT2 CNG is an important mechanism driving Ect2 overexpression in LSCCs ). In addition to LSCC, ovarian tumors also show tumor-specific amplification at 3q26 (Eder et al., 2005 , Zhang et al., 2006 . Ect2 is overexpressed in ovarian tumors harboring ECT2 amplification compared to whole normal ovary (Haverty, Hon, 2009) indicating that tumor-specific ECT2 amplification also drives Ect2 expression in ovarian tumors. Thus, a major mechanism driving Ect2 expression is tumor-specific amplification of ECT2 as part of the 3q26 amplicon.
PIK3CA encodes p110α, the catalytic subunit of phosphatidylinositol 3-kinase (PI3K). PI3-kinases mediate production of 3-phosphorylated phosphoinositides (PtdIns3P, PtdIns(3,5)P2 and PtdIns(3,4,5)P3) that serve as required second messengers for many physiological processes, including cell growth and proliferation, cell motility, survival, differentiation, cell adhesion, invasion, intracellular vesicular traffic, and protein synthesis. PIK3CA is frequently targeted for oncogenic activation either by somatic mutation or CNG as part of the 3q26 amplicon. PIK3CA is frequently mutated in breast, endometrial, colorectal, urinary tract and ovarian cancers (reviewed in (Yuan and Cantley, 2008) ). These mutations cluster in two conserved regions encoding the kinase and helical domains of the protein. These "hot spot" mutations, H1047R, E545K and E542K, are non-synonymous missense mutations that confer constitutive kinase activity . Amplification of PIK3CA has been found in primary ovarian tumors and ovarian cancer cell lines (Shayesteh et al., 1999) , primary cervical tumors and cervical cancer cell lines (Ma et al., 2000) , HNSCC primary tumors (Woenckhaus et al., 2002) and LSCC (Brass, Ukena, 1996) . PIK3CA gene amplification was initially observed in ovarian cancer where an increase in PIK3CA copy number was found to associate with an increased in transcription, p110α protein expression and PI3K activity (Shayesteh, Lu, 1999) . Similarly, in cervical tumors PIK3CA gene copy drives its overexpression (Ma, Wei, 2000) . CNGs in PIK3CA have been shown to correlate with its mRNA expression in HNSCC cell primary tumors (Redon et al., 2001 , Woenckhaus, Steger, 2002 . CNGs in PIK3CA are prevalent in thyroid cancer, particularly follicular thyroid carcinoma (FTC) and anaplastic thyroid carcinoma (ATC) sub-types which exhibit 24% and 42% CNG, respectively (Wu et al., 2005) . Several studies have shown that PIK3CA amplification is associated with overexpression of p110α in thyroid tumors (Hou et al., 2007 , Wu, Mambo, 2005 . Endometrial tumors with 3q amplification overexpress PIK3CA when compared with unamplified tumors (Salvesen et al., 2009 ). In a separate study, 9 of 15 (60.0%) gastric cancer cell lines and 17 of 55 (30.9%) primary gastric carcinomas harbored PIK3CA amplification, whereas no normal and benign tumor tissues showed abnormal amplification (Byun et al., 2003) . In addition, amplification of PIK3CA in gastric tumor cell lines was strongly associated with increased transcript level (Byun, Cho, 2003) . LSCC frequently harbor CNGs in PIK3CA (Massion, Kuo, 2002) and NSCLC cell lines harboring PIK3CA CNGs express higher PIK3CA mRNA levels when compared to cell lines without an increase in copy number (Yamamoto et al., 2008) .
PRKCI encodes a member of the atypical sub-class of the protein kinase C gene family, protein kinase C iota (PKCι). PKCι is a component of the cell polarity complex that functions to establish epithelial cell polarity, cell fate and tissue integrity of non-transformed cells, through regulation and subcellular localization of Rac1 and cdc42 (reviewed in (Vorhagen and Niessen, 2014) . PRKCI is overexpressed in many tumor types including breast, brain, cervix, chronic myelogenous leukemia (CML), colorectal, esophageal, gastric, head and neck, hepatocellular, kidney, lung, melanoma, ovarian, pancreatic, prostate, rhabdomyosarcoma and uterine (reviewed in (Murray et al., 2011) ). The overexpression of PKCι in tumors is associated with poor prognosis and reduced patient survival. PKCι expression is predictive of poor outcome in patients with bile duct , lung (Regala et al., 2005b) , ovarian (Eder, Sui, 2005 , Weichert et al., 2003 , pancreatic (Scotti et al., 2010) and prostate cancers (Ishiguro et al., 2011) . In some tumor types such as bile duct , breast (Kojima et al., 2008) , ESCC (Yang et al., 2008) , liver (Du et al., 2009 ) and ovarian (Zhang, Huang, 2006) , PKCι expression is higher in late stage cancers, suggesting that PKCι may promote higher grade, and a more aggressive phenotype in these tumors. In contrast, PKCι expression levels do not correlate with stage in NSCLC in which PKCι overexpression was frequently observed in early stage (stage I and II) tumors (Regala, Weems, 2005b) . Interestingly, patients with gastric tumors that have higher PKCι expression are more likely to relapse (Takagawa et al., 2010) . Thus PKCι expression may Fields et al. Page 9 Adv Biol Regul. Author manuscript; available in PMC 2017 January 01.
serve as an important prognostic marker to identify patients who may be at elevated risk for tumor progression and relapse, and these patients may benefit from early and more aggressive adjuvant anti-tumor therapies.
PRKCI is frequently amplified in NSCLC, and amplification drives PKCι expression in NSCLC primary tumors and established cell lines (Regala, Weems, 2005b) . Disruption of PKCι signaling blocks transformed growth of NSCLC cell lines with PRKCI amplification, demonstrating that PKCι is a critical target of 3q26 amplification in NSCLC. PRKCI amplification is associated with lymph node metastases in ESCC, and PKCι promotes metastasis of ESCC cell lines (Liu et al., 2011b , Yang, Chu, 2008 . Likewise, PKCι has been characterized as an oncogene in ovarian cancer. PRKCI is frequently amplified and overexpressed in ovarian serous cancer and PRKCI amplification predicts poor patient survival (Eder, Sui, 2005) . In summary, PKCι is highly expressed in 3q26 amplified tumors, suggesting an oncogenic role for PKCι in these tumors. Interestingly however, PKCι is overexpressed in a vast majority of tumor types, including many that do not harbor frequent 3q26 CNGs, indicating that multiple mechanisms are at play to ensure high oncogenic PKCι expression in the majority of human cancer types.
The core 3q26 nodal genes act as a highly coordinated "OncCassette" that drives tumorigenesis
As described above, each of the four 3q26 nodal genes, SOX2, ECT2, PIK3CA and PRKCI, have individually been shown to function in the establishment and maintenance of the transformed phenotype of 3q26 driven tumors. It is also quite evident that these genes operate in a tumor environment in which they are coordinately amplified and overexpressed in tumors harboring 3q26 CNGs, demonstrating that these genes are genetically integrated with the oncogenic behavior of these tumors. Interestingly however, our genomic analysis suggests an even higher level of integration among these genes; specifically that these genes reside within a single network module in the context of 3q26 amplified tumors (Figure 3) . Indeed, accumulating evidence from a number of biochemical, cellular signaling and cell biological studies provide compelling evidence that these four genes are functionally and biochemically linked in these tumors. Below we highlight major studies demonstrating this functional integration among 3q26 nodal genes.
The 3q26 genes EVI1 and PIK3CA regulate expression of a third 3q26 gene, SKIL/SNO-SKIL (alias SNO) (ski-related novel gene) is a member of the Ski family of nuclear oncoproteins that repress transforming growth factor-beta (TGF-beta) signaling through inhibition of transcriptional activity of Smad proteins (Sarker et al., 2005) . SKIL/ SNO, which resides at 3q26, was found to be consistently over-expressed in ESCC cell lines and primary tumors that exhibit 3q26 amplification, suggesting that this gene is a potential target of 3q26 amplification (Imoto et al., 2001) . A study to identify candidate target genes for yet another 3q26 gene EVI1, that may play a role in EVI1-dependent transformation revealed that EVI1 can occupy the SKIL/SNO promoter and regulate SKIL expression (Yatsula et al., 2005) . In ovarian cancer cells, the PI3K/AKT signaling pathway transcriptionally up-regulates SKIL expression in response to As2O3 (a drug exhibiting anti- tumor activity), and expression of siRNA targeting PIK3CA abrogated this response in ovarian cancer cells (Kodigepalli et al., 2013) .
PKC;ι and Ect2 cooperate in Rac1 activation and lung transformation-In NSCLC cells, the protein product of the 3q26 gene PRKCI, PKCι resides in an oncogenic complex with the polarity associated protein Par6, an interaction that functions to drive anchorage-independent growth and invasion through activation of the Rho family GTPase Rac1 (Frederick et al., 2008) . In an effort to biochemically characterize the mechanism by which the PKCι-Par6 complex regulates Rac1 activity in LSCC cells, we performed a proteomic screen to identify proteins that associate with the PKCι-Par6 complex and participate in PKCι signaling in NSCLC ). We identified Ect2, a gene co-localized on the frequently amplified 3q26 chromosomal region , as a component of the oncogenic PKCι-Par6 complex in LSCC cells. Like PKCι and Par6, RNAi-mediated knockdown of Ect2 in NSCLC cells inhibits Rac1 activation and transformation. We further demonstrated that the oncogenic potential of Ect2 requires its interaction with PKCι-Par6 ). Thus, two 3q26 nodal genes, PRKCI and ECT2 are coordinately amplified and overexpressed in LSCC tumors, and the protein products of these genes biochemically interaction in an oncogenic complex in these cells.
The transformed behavior of LSCC cells requires both formation of the PKCι-Par6 complex and PKCι kinase activity (Frederick, Matthews, 2008) . We therefore reasoned that substrates important for PKCι-mediated transformation might be identified within the PKCι-Par6 complex. Indeed, in a companion study, we demonstrated that PKCι can directly phosphorylate Ect2 (Justilien, Jameison, 2011) . Mass spectrometry (MS) analysis of recombinant Ect2 incubated with PKCι in vitro revealed that Ect2 was phosphorylated on T328, a consensus PKCι phosphorylation site predicted by the kinase phosphorylation site prediction program Net-PhosK ). Furthermore, we showed that this phosphorylation event regulates Ect2 activation of Rac1 and transforming potential to maintain the transformed phenotype of NSCLC cells (Justilien, Jameison, 2011) . Therefore, Ect2 and PKCι drive tumor cell proliferation through formation of an oncogenic PKCι-Par6-Ect2 complex.
Studies in primary LSCC tumors demonstrated that PRKCI and ECT2 are coordinately amplified and overexpressed in LSCC tumors ). Thus, Ect2 and PKCι are genetically linked through coordinate gene amplification in LSCC, and biochemically and functionally linked in LSCC through formation of an oncogenic PKCι-Par6-Ect2 complex that drives NSCLC cell transformation by activating Rac1 Fields, 2009, Justilien, Jameison, 2011) . Finally, PKCι utilizes Ect2 as a direct substrate and through direct, site-specific phosphorylation, regulates the oncogenic activity of Ect2. adenocarcinoma (LADC) (Regala et al., 2009 ). In this model, PKCι is required for the transformation and growth of TICs that give rise to LADC (Regala, Davis, 2009 ). This study led us to hypothesize that the oncogenic function of PKCι is to establish and maintain a TIC phenotype in LSCC tumors harboring 3q26 CNG as well. In a subsequent study, we demonstrated that indeed PKCι functions to maintain a TIC phenotype in human LSCC (Justilien, Walsh, 2014) . Functional analysis demonstrated that PRKCI cooperates with SOX2, a second 3q26 nodal gene, to drive a TIC phenotype in LSCC cells and primary LSCC tumors (Justilien, Walsh, 2014) . PKCι maintains the TIC phenotype in LSCC through SOX2-mediated regulation of Hh signaling (Justilien, Walsh, 2014) . Mechanistically, PKCι phosphorylates SOX2 at T118, a phosphorylation event that drives SOX2-mediated transcriptional activation of Hedgehog acetyl transferase (HHAT), an enzyme that catalyzes a critical step in the maturation of Hh ligand. Thus PRKCI and SOX2 cooperate to regulate a cell autonomous Hh signaling axis that maintains the TIC phenotype in LSCC.
Taken together, these biochemical and functional studies provide a compelling picture of the 3q26 amplicon as a highly coordinated, functionally integrated 3q26 OncCassette consisting of 4 core 3q26 nodal genes, SOX2, ECT2, PRKCI and PIK3CA. The 3q26 OncCassette drives tumorigenesis through coordinated overexpression of these 4 oncogenic genes that reside in a single integrated signaling network that functions to establish and maintain a population of highly aggressive and tumorigenic stem-like cells that drive tumor formation, survival, proliferation, and progression to a highly metastatic phenotype (Figure 4 ). In addition, many the non-3q26 components of the 3q26 OncCassette induced signaling pathways outlined in Figure 4 have been implicated in the establishment and maintenance of a cancer stem-like phenotype including EGFR, KRAS and PTEN (Ciuffreda et al., 2014 , McCubrey et al., 2015 .
Therapeutic Implications: Targeting the 3q26 OncCassette
The realization that 3q26 CNG drives oncogenesis through coordinated overexpression of biochemically and functionally linked genes presents both challenges and opportunities for therapeutic intervention. Inspection of the nodal and integrated 3q26 genes ( Figure 3 ) and their experimentally validated signaling interactions (Figure 4 ) reveals multiple avenues for drug development. Several 3q26 nodal genes are direct druggable targets (i.e. PIK3KCA and PRKCI). Other 3q26 genes belonging to the predicted network module are also potentially druggable enzymes including PLD1 (Gomez-Cambronero, 2014 ) and the PTEN signaling axis (Ciuffreda, Falcone, 2014) . Furthermore, the four nodal 3q26 OncCassette genes function within the context of signaling pathways that represent even more druggable targets for therapeutic exploitation. The most developmentally advanced inhibitors targeting a 3q26 gene are the PIK3CA inhibitors (reviewed in (Garcia-Echeverria and Sellers, 2008, Rodon et al., 2013) ). Though PI3K inhibitors showed great promise in pre-clinical studies, their clinical use has been limited by unacceptable toxicity profiles and detrimental off-target effects. Second generation inhibitors targeting various points in the PI3K signaling axis, including inhibitors of AKT, specific PI3K isoforms which serve distinct roles in tumorigenesis (Baer et al., 2015) , and dual inhibitors of PI3K and mTOR, and PI3K and PLK1, have shown promise as anti-tumor agents (Bowles et al., 2014 , Roychowdhury et al., 2010 , Serra, Markman, 2008 More recently, PKCι inhibitors have been identified and validated in pre-clinical studies (Butler et al., 2015 , Erdogan et al., 2006 , Fields and Murray, 2008 , Kjaer et al., 2013 , Parker et al., 2014 . We identified the anti-rheumatoid gold salts aurothiomalate (ATM) and auranofin (ANF) as potent and selective PKCι inhibitors that function through disruption of the interaction between oncogenic PKCι and its binding partner Par6 (Erdogan, Lamark, 2006 , StallingsMann, Jamieson, 2006 . A major advantage of these compounds is that they are FDAapproved and have favorable toxicity profiles that make them suitable for use in the oncology setting. Both ATM and ANF exhibit potent anti-tumor activity in vitro and in vivo in lung, ovarian and pancreatic tumor models (Butler, Scotti Buzhardt, 2015 , Erdogan, Lamark, 2006 , Stallings-Mann, Jamieson, 2006 , Wang et al., 2013b . Interestingly, response to ATM and ANF correlates directly with PRKCI CNG and elevated PKCι expression, indicating that 3q26 CNG-driven tumors may be particularly sensitive to PKCι inhibitor therapy (Regala et al., 2008) . Our initial clinical experience with these agents has demonstrated proof of principle for PKCι inhibition using ATM or ANF as a viable therapeutic approach in both LSCC and ovarian serous cancer, tumor types exhibiting frequent 3q26 CNGs (Jatoi et al., 2014 , Mansfield et al., 2013 . These agents were well tolerated in the oncology setting at concentrations that exhibit effective anti-tumor activity, and these agents have shown promising initial indications of clinical activity in heavily pretreated patients with advanced disease. More recently, we have demonstrated synergistic anti-tumor activity when combining ANF with mTOR inhibition, a combination that effectively targets both the PKCι and PI3K-AKT-mTOR pathways shown in Figure 4 . This combination has shown good synergistic anti-tumor activity in pre-clinical models of 3q26 CNG-driven LSCC in vitro and in vivo (manuscript in preparation). An ongoing phase 1B/II clinical trial using ANF combined with the mTOR inhibitor sirolimus is currently accruing patients with advanced LSCC. Similarly, ANF exhibits synergistic anti-tumor activity in combination with the Smoothened inhibitor erismodegib (Justilien and Fields, 2015) , a drug combination that effectively targets the recently identified PKCι-SOX2-Hh signaling axis that maintains a stem-like phenotype in 3q26 CNG LSCC (Justilien, Walsh, 2014) . These findings provide a compelling rationale for therapeutic approaches involving PKCι inhibition in combination with other targeted agents against signaling pathways that are activated and driven by the 3q26 OncCassette. This functionally rationalized approach to combined therapy for 3q26 driven tumors may be paradigm shifting with regard to the clinical treatment of the large number of human tumors harboring this common genetic alteration.
In conclusion, characterization of a functionally integrated, multigenic 3q26 OncCassette reveals a novel network module comprised of a genetically induced and functionally integrated set of oncogenic drivers. Combination therapies targeting nodal genes within this network show promise for enhancing clinical outcome of 3q26 amplified cancers. Further functional characterization of the 3q26 OncCassette holds considerable promise of revealing further opportunities for development of novel combined therapeutic intervention strategies that target unique vulnerabilities of 3q26 CNG driven tumors. The prevalence of 3q26 CNGs were assessed by interrogation of TCGA datasets for major tumor types using the cBioPortal tools as described in Materials and Methods. 50 genes corresponding to the core 3q26 amplicon in human tumors that also map to mouse chromosome 3 LSCC susceptibility locus are shown (see text for details). The color coded regions indicate sub-sections of the syntenic human and mouse chromosomes indicating evolutionary rearrangements and inversions in this region. Genes indicated in bold, italics correspond to genes within this syntenic region whose expression correlates with the presence of CNGs at that locus in human LSCC tumors. These genes were subjected to pathway analysis as described in the text. The core 3q26 amplicon genes identified in Figure 2 were subjected to gene set analysis using the ConsensuPathDB-human (CPDB; http://cpdb.molgen.mpg.de/CPDB) tool. 21 of the 35 core 3q26 genes reside within a single induced network module consisting of four nodal hub genes, SOX2, ECT2, PRKCI and PIK3CA, around which the module is organized. A schematic diagram is shown illustrating the integrated functional and biochemical relationships between the four 3q26 nodal genes SOX2, ECT2, PRKCI and PIK3CA. Functional studies demonstrate that these four nodal genes constitute a 3q26 OncCassette that establishes and maintains a highly tumorigenic tumor-initiating cell (TIC) phenotype that drives LSCC tumorigenesis. Genes in yellow indicate non 3q26 oncogenes; Genes in orange indicate the four 3q26 nodal genes; genes in blue indicate tumor suppressor genes; genes in gray indicate potential surrogate biomarkers of 3q26 OncCassette activity. 
